FEDERAL REGISTER INDEX
January–April 2014

Food and Drug Administration

RULES

Administrative Detention; Corrections – *9412 (Feb 19)*
Draft Guidance for Industry and Staff:
- Establishment, Maintenance, and Availability of Records – *18799 (Apr 4)*
- Good Manufacturing Practices, Quality Control Procedures, Quality Factors, Notification Requirements, and Records and Reports, for Infant Formula – *7933 (Feb 10)*
- Good Manufacturing Practices, Quality Control Procedures, Quality Factors, Notification Requirements, and Records and Reports, for Infant Formula; Correction – *9412 (Feb 19)*
- Medicated Feeds; Manufacturing Practice – *3738 (Jan 23)*
- Pharmacy Compounding Advisory Committee; Charter Changes – *2093 (Jan 13)*

Food Additives; Animals Feeds:
- Benzoic Acid – *14175 (Mar 13)*

Food Additives; Human Consumption:
- Spirulina Extract; Color Additives; Exempt from Certification – *20095 (Apr 11)*
- Vitamin D2 in Bakers Yeast – *13540 (Mar 11)*

Food Labeling:
- Irradiation in the Production, Processing, and Handling of Food – *10353 (Feb 25); 20771 (Apr 14)*
- Nutrient Content Claims; Alpha-Linolenic Acid, Eicosapentaenoic Acid, and Docosahexaenoic Acid Omega-3 Fatty Acids – *23262 (Apr 28)*

Maximum Civil Money Penalty Amounts; Civil Money Penalty Complaints – *6088 (Feb 3)*
Medical Devices:
- Classification of the Neuropsychiatric Interpretive Electroencephalograph Assessment Aid – *9083 (Feb 18)*
- Electronic Submission Requirements – *8832 (Feb 14)*
- General and Plastic Surgery Devices; Classification of the Absorbable Lung Biopsy Plug – *13218 (Mar 10)*
- Immunology and Microbiology Devices; Classification of John Cunningham Virus Serological Reagents – *3739 (Jan 23)*
- Ophthalmic Devices; Classification of the Eyelid Weight – *22012 (Apr 21)*
- Pediatric Uses of Devices; Requirement for Submission of Information – *1735 (Jan 10)*
- Reclassification of Stair-Climbing Wheelchairs – *20779 (Apr 14)*
- Reports of Corrections and Removals; Technical Amendment – *9413 (Feb 19)*

Meetings:
- Bone, Reproductive and Urologic Drugs Advisory Committee; Charter Changes – *20094 (Apr 11)*

New Animal Drugs:
- Amprolium; Bambermycins; Ceftiofur; Deslorelin; Florfenicol; Florfenicol and Flunixin; Paclitaxel; Phenylbutazone; Pimobendan; Salinomycin; Tilmicosin; Tiludronate – *18156 (Apr 1)*
- Argent Laboratories; Formalin; Tricaine Methanesulfonate; Withdrawal – *2785, 2786 (Jan 16)*
- Bambermycins, Hygromycin B, Lincomycin, Pyrantel, Tylosin, Tylosin and Sulfamethazine, Virginiamycin – *19814, 19816 (Apr 10)*
- Bambermycins; Clopidol; Ivermectin; et al.; Change of Sponsor; Change of Sponsor Address – *10963 (Feb 27)*
- Ceftiofur Sodium; Gentamicin; Xylazine – *21126 (Apr 15)*
- Changes of Sponsors – *10965 (Feb 27); 13542 (Mar 11)*
- Chlortetracycline; Sulfathiazole; Penicillin; Withdrawal – *15540, 15541 (Mar 20)*
- Confidentiality of Data and Information in a New Animal Drug Application File – *14609 (Mar 17)*
- Implantation or Injectable Dosage Form; Change of Sponsor – *16180 (Mar 25)*
- Zoetis Inc., et al.; Medicated Feeds Containing an Arsenical Drug; Correction – *18990 (Apr 7)*
- Zoetis Inc., et al.; Withdrawal of Approval; Combination Drug Medicated Feeds Containing an Arsenical Drug – *10974, 10976 (Feb 27)*
- Zoetis, Inc., al.; Combination Drug Medicated Feeds Containing a Arsenical Drug; Correction – *17859 (Mar 31)*

Premarket Approvals:
- Transilluminator for Breast Evaluation and Sorbent Hemoperfusion System Devices for Treatment of Hepatic Coma and Metabolic Disturbances; etc. – *3088 (Jan 17)*

PROPOSED RULES

Draft Guidance for Industry and Staff:
- Current Good Manufacturing Practice and Hazard Analysis and Risk-Based Preventive Controls for Food for Animals – *6111 (Feb 3)*
- Demonstration of the Quality Factor Requirements for Eligible Infant Formulas; Availability – *7609 (Feb 10)*
- Draft Qualitative Risk Assessments; Outside the Farm Definition – *16251 (Mar 25)*
- Exempt Infant Formula Production; Current Good Manufacturing Practices, Quality Control Procedures, Conduct of Audits, and Records and Reports; Availability – *7610 (Feb 10)*
- Focused Mitigation Strategies to Protect Food Against Intentional Adulteration – *16251 (Mar 25)*
- Focused Mitigation Strategies to Protect Food Against Intentional Adulteration; Meetings – *5353 (Jan 31)*
- Imported Food Questions and Answers – *17947 (Mar 31)*
- Qualitative Risk Assessment of Risk of Activity/Animal Food Combinations; Conducted in a Facility Co-Located on a Farm – *6116 (Feb 3)*
- Records Access Authority under the Federal Food, Drug, and Cosmetic Act – *18866 (Apr 4)*
- Sanitary Transportation of Human and Animal Food – *7005 (Feb 5)*
- What You Need To Know About Establishment, Maintenance, and Availability of Records; Small Entity Compliance Guide – *18867 (Apr 4)*

Environmental Impact Statements; Availability, etc.:
- Standards for Growing, Harvesting, Packing, and Holding of Produce for Human Consumption – *13593 (Mar 11)*

Food Additive Petitions; Animal Use:
- Novus International, Inc. – *22910 (Apr 25)*

Food Additives; Animal Use:
- DSM Nutritional Products – *16252 (Mar 25); 16698 (Mar 26)*
- Excentials B.V. – *22602 (Apr 23)*
- Kemin Industries, Inc. – *13263 (Mar 10)*
- Lohmann Animal Health GMBH – *7611 (Feb 10)*

Food Additives; Petitions:
- Eastman Chemical Co. – *19301 (Apr 8)*

Food Labeling:
- Revision of the Nutrition and Supplement Facts Labels – *11879 (Mar 3)*
- Serving Sizes of Foods that Can Reasonably Be Consumed at One-Eating Occasion, etc. – *11989 (Mar 3)*
- Serving Sizes; Reference Amount and Serving Size Declaration for Hard Candies, Breath Mints – *11738 (Mar 3)*

Food Safety Modernization Act:
- Food Registry Provisions of Federal Food, Drug, and Cosmetic Act; Amendments – *16698 (Mar 26)*

Generic Drug User Fee Amendments:
- Regulatory Science Initiatives; Public Hearing – *10740 (Feb 26)*

Maximum Civil Money Penalty Amounts; Civil Money Penalty Complaints – *6112 (Feb 3)*
Medical Devices:
- Medical Device Classification Procedures – *16252 (Mar 25)*

National Environmental Policy Act:
- Tobacco Products; Categorical Exclusions – *3742 (Jan 23)*

New Animal Drugs:
- Confidentiality of Data and Information in a New Animal Drug Application File – *14630 (Mar 17)*

Physical Medicine Devices:

Action Plan for Collection, Analysis, and Availability of Demographic Subgroup Data; Regulated Medical Products; Public Hearings – *12134 (Mar 4)*
Cardiovascular Devices; Nonroller-Type Cardiopulmonary Bypass Blood Pumps for Cardiopulmonary and Circulatory Bypass; etc.; Reclassification – *765 (Jan 7)*
Premarket Approval for Shortwave Diathermy for All Other Uses; Withdrawal – *9670 (Feb 20)*
Shortwave Diathermy for All Other Uses; Reclassification – *9671 (Feb 20)*
Sanitary Transportation of Human and Animal Food – *8907 (Feb 14)*
Tobacco Products:
Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products – *23141 (Apr 25)*

NOTICES

Agency Information Collection Activities; Proposals, Submissions, and Approvals:
Additional Criteria and Procedures for Classifying Over-the-Counter Drugs as Generally Recognized as Safe and Effective and Not Misbranded – *16007 (Mar 24)*
Adverse Event Program for Medical Devices (Medical Product Safety Network) – *20887 (Apr 14)*
Adverse Experience Reporting for Licensed Biological Products; and General Records – *19097 (Apr 7)*
Animal Drug User Fee Act Cover Sheet – *6199 (Feb 3); 22689 (Apr 23)*
Animal Drug User Fee Act Waivers and Reductions – *10532 (Feb 25)*
Animal Feed Network; State, Federal Cooperation to Prevent Spread of Pet Food and Animal Feed Related Diseases – *10529 (Feb 25)*
Animal Feed Regulatory Program Standards – *9223 (Feb 18)*
Animal Generic Drug User Fee Act Cover Sheet – *9224 (Feb 18); 22687 (Apr 23)*
Application for Food and Drug Administration Approval to Market a New Drug – *16003 (Mar 24)*
Application for Participation in the Medical Device Fellowship Program – *3819 (Jan 23); 19619 (Apr 9)*
Chemistry, Manufacturing, and Controls Postapproval Manufacturing Changes to be Documented in Annual Reports – *9215 (Feb 18)*
Color Additive Certification Requests and Recordkeeping – *7199 (Feb 6); 22688 (Apr 23)*
Cosmetic Labeling Regulations – *21766 (Apr 17)*
Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements – *10530 (Feb 25)*
Current Good Manufacturing Practice Regulations for Medicated Feeds – *19091 (Apr 7)*
Current Good Manufacturing Practice Regulations for Type A Medicated Articles – *19093 (Apr 7)*
Current Good Manufacturing Practice; Quality System Regulation – *9908 (Feb 21)*
Customer/Partner Service Surveys – *21765 (Apr 17)*
Data to Support Drug Product Communications as Used by the Food and Drug Administration – *19096 (Apr 7)*
Designation of New Animal Drugs for Minor Use or Minor Species; Final Rule – *14713 (Mar 17)*
Electronic Records; Electronic Signatures – *17551 (Mar 28)*
Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products – *16800 (Mar 26)*
Establishing and Maintaining Lists of United States Milk Product Manufacturers/Processors with Interest in Exporting – *9221 (Feb 18)*
Evaluation of the General Market Youth Tobacco Prevention Campaign – *11112 (Feb 27)*
Exception from General Requirements for Informed Consent – *19915 (Apr 10)*
Exceptions or Alternatives to Labeling Requirements for Products Held by the Strategic National Stockpile – *9219 (Feb 18)*
Eye Tracking Experimental Studies to Explore Consumer Use of Food Labeling Information, etc. – *14713 (Mar 17)*
Focus Groups as Used by the Food and Drug Administration – *9222 (Feb 18)*
Food and Drug Administration Generic Rapid Response Surveys – *19618 (Apr 9)*
Food and Drug Administration Safety Communication Readership Survey – *7677 (Feb 10)*
General Administrative Procedures: Citizen Petitions; Petition for Reconsideration or Stay of Action; Advisory Opinions – *15594 (Mar 20)*
General Licensing Provisions: Biologics License Application, Changes, etc. – *3821 (Jan 23)*
Guidance for Industry and Food and Drug Administration Staff on Improving Communication of Important Safety Information – *3209 (Jan 17)*
Guidance for Industry on Citizen Petitions and Petitions for Stay of Action Subject to the Federal Food, Drug, and Cosmetic Act – *13656 (Mar 11)*
Guidance for Industry on Pharmacogenomic Data Submissions – *7198 (Feb 6)*
Guidance for Industry on Updating Labeling for Susceptibility Test Information in Systemic Antibacterial Drug Products, etc. – *19099 (Apr 7)*
Guide to Minimize Microbial Food Safety Hazards of Fresh-Cut Fruits and Vegetables – *4350 (Jan 27)*
Hazard Analysis and Critical Control Point Procedures for the Safe and Sanitary Processing and Importing of Juice; Comment Request – *4347 (Jan 27)*
Human Cells, Tissues, and Cellular and Tissue-Based Products, etc. – *3822 (Jan 23)*
Human Tissue Intended for Transplantation – *9467 (Feb 19)*
Importer's Entry Notice – *14255 (Mar 13)*
Index of Legally Marketed Unapproved New Animal Drugs for Minor Species – *19094 (Apr 7)*
Information from United States Firms and Processors that Export to the European Community – *11446 (Feb 28)*
Institutional Review Boards – *12202 (Mar 4)*
Investigational New Drug Safety Reporting Requirements for Human Drug and Biological Products, etc. – *3826 (Jan 23)*
Medical Devices; Device Tracking – *22991 (Apr 25)*
Medical Devices; Third Party Review under the Food and Drug Administration Modernization Act – *9215 (Feb 18)*
Orphan Drugs Products; Common European Medicines Agency/FDA Application Form for Orphan Medicinal Product Designation – *21471 (Apr 16)*
Over-the-Counter Human Drugs; Labeling Requirements – *9217 (Feb 18)*
Patent Term Restoration, Due Diligence Petitions, Filing, Format, and Content of Petitions – *7678 (Feb 10)*
Potential Tobacco Product Violations Reporting Form – *9216 (Feb 18)*
Premarket Approval of Medical Devices – *3210 (Jan 17)*
Premarket Notification for a New Dietary Ingredient – *15129 (Mar 18)*
Premarket Notification Submission 510(k) – *3210 (Jan 17)*
Preparing a Claim of Categorical Exclusion or an Environmental Assessment for Submission to the Center for Food Safety and Applied Nutrition – *15130 (Mar 18)*
Prescription Drug Advertisements – *11112 (Feb 27)*
Procedures for the Safe Processing and Importing of Fish and Fishery Products – *14713 (Mar 17)*
Protection of Human Subjects; Informed Consent; Institutional Review Boards – *3826 (Jan 23)*
Qualitative Feedback on Agency Service Delivery – *23980 (Apr 29)*
Radioactive Drug Research Committees – *4348 (Jan 27); 24442 (Apr 30)*
Recommended Glossary and Educational Outreach to Support Use of Symbols on Labels and in Labeling of In Vitro Diagnostic Devices, etc. – *3820 (Jan 23); 16799 (Mar 26)*
Recordkeeping and Records Access Requirements for Food Facilities – *21767 (Apr 17)*
Reporting and Recordkeeping for Electronic Products; General Requirements – *3210 (Jan 17)*
Reports of Corrections and Removals of Medical Devices and Radiation Emitting Products – *17549 (Mar 28)*
Requests for Feedback on Medical Device Submissions – *3821 (Jan 23)*
Risk and Benefit Perception Scale Development – *22143 (Apr 21)*
Risks in Direct-to-Consumer Prescription Drug Television Advertisements – *9217 (Feb 18)*
Standards for Interoperable Exchange of Information for Tracing of Human, Finished, Prescription Drugs, in Paper or Electronic Format – *9745 (Feb 20)*
Submission of Petitions; Food Additive, Color Additive, and Generally Recognized as Safe Affirmation, etc. – *21469 (Apr 16)*
Testing Communications on Medical Devices and Radiation-Emitting Products – *18558 (Apr 2)*
Tobacco Health Document Submission – *3820 (Jan 23)*
Total Product Life Cycle; Infusion Pump; Premarket Notification Submissions; Draft Guidance for Industry and Staff – *19616 (Apr 9)*

Use of Serological Tests to Reduce the Risk of Transmission of Trypanosoma cruzi Infection in Whole Blood and Blood Components for Transfusion – *12506 (Mar 5)*
User Fee Waivers, Reductions, and Refunds for Drug and Biological Products – *12201 (Mar 4)*
Voluntary Cosmetic Registration Program – *7196 (Feb 6); 23981 (Apr 29)*
Voluntary National Retail Food Regulatory Program Standards – *6200 (Feb 3)*
Determinations that Products Were Not Withdrawn from Sale for Reasons of Safety or Effectiveness:
Cefmetazole Sodium Injection, Equivalent to 1 Gram Base/Vial and Equivalent to 2 Gram Base/Vial, etc. – *13307 (Mar 10)*
Darunavir Tablets, 400 Milligrams – *18558 (Apr 2)*
Gallium Nitrate Injectable and Five Other Drug Products – *9225 (Feb 18)*
Metaxalone Tablets, 400 Milligrams – *19102 (Apr 7)*
Nimodipine Capsules, 30 Milligrams – *18559 (Apr 2)*
Valproic Acid Delayed-Release Capsules, 125 Milligrams, 250 Milligrams, and 500 Milligrams – *9225 (Feb 18)*
Zovirex Injection, Equivalent to 250 Milligrams Base/Vial, et al. – *20214 (Apr 11)*
Draft Guidance for Industry and Staff:
Advisory Committee Members' Financial Interest Information and Waivers – *18032 (Mar 31)*
Allowable Excess Volume and Labeled Vial Fill Size in Injectable Drug and Biological Products – *14517 (Mar 14)*
Analgesic Indications; Developing Drug and Biological Products – *7203 (Feb 6)*
Analytical Procedures and Methods Validation for Drugs and Biologics – *9467 (Feb 19)*
Attachment to Guidance on Antiviral Product Development; Conducting and Submitting Virology Studies to the Agency; etc. – *11448 (Feb 28)*
Balancing Premarket and Postmarket Data Collection for Devices Subject to Premarket Approval – *22690 (Apr 23)*
Bioavailability and Bioequivalence Studies Submitted in New Drug Applications or Investigational New Drug Applications – *15131 (Mar 18)*
Biologics License Applications for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood, etc. – *12508 (Mar 5)*
Blood Glucose Monitoring Test Systems for Prescription Point-of-Care Use – *830 (Jan 7); 19622 (Apr 9)*
Center for Biologics Evaluation and Research Move to White Oak Campus – *12506 (Mar 5)*
Center for Devices and Radiological Health – *16801 (Mar 26)*
Chemistry, Manufacturing, and Controls Postapproval Manufacturing Changes to be Documented in Annual Reports – *12511 (Mar 5)*
Chronic Fatigue Syndrome/Myalgic Encephalomyelitis; Development of Drug Products for Treatment; Availability – *13658 (Mar 11)*
Community-Acquired Bacterial Pneumoni; Developing Drugs for Treatment – *1874 (Jan 10)*
Considerations Regarding Substances Added to Foods, Including Beverages and Dietary Supplements – *2450 (Jan 14)*
Custom Device Exemption – *2446 (Jan 14)*
Dear Health Care Provider Letters; Improving Communication of Important Safety Information – *3827 (Jan 23)*
Designation of High-Risk Foods for Tracing – *6596 (Feb 4)*
Designation of High-Risk Foods for Tracing and for Scientific Data and Information – *16800 (Mar 26)*
Determining whether Human Research Studies can be Conducted without an Investigational New Drug Application; Reopening of the Comment Period – *7204 (Feb 6)*
Distinguishing Liquid Dietary Supplements from Beverages – *2451 (Jan 14)*
Distributing Scientific and Medical Publications on Unapproved New Uses - Recommended Practices – *11793 (Mar 3)*
Endotoxin Testing Recommendations for Single-Use Intraocular Ophthalmic Devices – *21777 (Apr 17)*
Enforcement Policy for Certain Tobacco Products that the Food and Drug Administration Finds Not Substantially Equivalent – *10534 (Feb 25)*
Enforcement Policy Regarding Investigational New Drug Requirements for Use of Fecal Microbiota for Transplantation to Treat Clostridium difficile Infection Not Responsive to Standard Therapies – *10814 (Feb 26)*
Expedited Access for Premarket Approval Medical Devices Intended for Unmet Medical Need for Life Threatening or Irreversibly Debilitating Disease or Conditions – *22691 (Apr 23)*
Fees for Human Drug Compounding Outsourcing Facilities under the Food, Drug, and Cosmetic Act – *18297 (Apr 1)*
Fulfilling Regulatory Requirements for Postmarketing Submissions of Interactive Promotional Media for Prescription Human and Animal Drugs and Biologics – *2449 (Jan 14)*
Guidance for Industry on Pharmacogenomic Data Submissions – *23359 (Apr 28)*
Guidance for Industry on Special Protocol Assessment – *7676 (Feb 10)*
Humanitarian Device Exemption, Questions and Answers – *15130 (Mar 18)*
Immunogenicity-Related Considerations for Approval of Low Molecular Weight Heparin for New Drug Applications – *19621 (Apr 9)*
Ingredients Declared as Evaporated Cane Juice Ingredients – *12507 (Mar 5)*
International Conference on Harmonisation; E2B(R3) Electronic Transmission of Individual Case Safety Reports, etc. – *9908 (Feb 21)*
Interpreting Sameness of Monoclonal Antibody Products under Orphan Drug Regulations – *22693 (Apr 23)*
Investigational New Drug Applications for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood, etc. – *12509 (Mar 5)*
Labeling for Human Prescription Drug and Biological Products Approved under the Accelerated Approval Regulatory Pathway – *16344 (Mar 25)*
Live Case Presentations During Investigational Device Exemption Clinical Trials – *21776 (Apr 17)*
Meaning of "Spouse" and "Family" in FDA Regulations after United States v. Windsor – *18693 (Apr 3)*
Medical Devices Containing Materials Derived From Animal Sources – *3826 (Jan 23)*
Meetings with the Office of Orphan Products Development – *19623 (Apr 9)*
New Chemical Entity Exclusivity Determinations for Fixed-Combination Drug Products – *10167 (Feb 24)*
Pediatric Studies; Sodium Nitroprusside; Summary Report, Labeling Changes – *4167 (Jan 24)*
Premarket Approval Applications; Annual Reports – *7679 (Feb 10)*
Premarket Notification Submissions for Bipolar Electrosurgical Vessel Sealers for General Surgery – *16009 (Mar 24)*
Premarket Notification Submissions for Electrosurgical Devices for General Surgery – *16008 (Mar 24)*
Product-Specific Bioequivalence Recommendations – *18561 (Apr 2)*
Proper Labeling of Honey and Honey Products – *19620 (Apr 9)*
Providing Regulatory Submissions in Electronic Format--Standardized Study Data; Revision – *7201 (Feb 6)*
Providing Regulatory Submissions in Electronic Format--Submissions under the Federal Food, Drug, and Cosmetic Act – *7200 (Feb 6)*
Providing Regulatory Submissions in Electronic Format; Receipt Date; Correction – *11449 (Feb 28)*
Qualification of Exacerbations of Chronic Pulmonary Disease Tool for Measurement of Symptoms of Acute Bacterial Exacerbation of Chronic Bronchitis, etc. – *1873 (Jan 10)*
Qualification Process for Drug Development Tools – *831 (Jan 7)*
Questions and Answers About Electronic Medical Device Reporting – *8977 (Feb 14)*
Regulatory Submissions in Electronic Format – *7463 (Feb 7)*
Report on Performance of Drug and Biologics Firms in Conducting Postmarketing Requirements and Commitments – *9230 (Feb 18)*
Reporting of Computational Modeling Studies in Medical Device Submissions – *3211 (Jan 17)*
Reports to Congress; Premarket Notification Requirements for Modifications to Legally Marketed Devices – *12695 (Mar 6)*
Requests for Feedback on Medical Device Submissions; Pre-Submission Program and Meetings with FDA Staff – *9226 (Feb 18)*
Self-Monitoring Blood Glucose Test Systems for Over-the-Counter Use – *829 (Jan 7); 19622 (Apr 9)*
Study Data Technical Conformance Guide and Data Standards Catalog – *7204 (Feb 6)*
Submitting Food Canning Establishment Registration Form, etc., in Electronic or Paper Format – *2448 (Jan 14)*
Training Program for Regulatory Project Managers; Information Available to Industry – *9912 (Feb 21)*
Transparency Initiative – *22693 (Apr 23)*
Types of Communication During the Review of Medical Device Submissions – *18918 (Apr 4)*
Drugs for Human Use:
Certain Prescription Drugs Offered for Various Indications – *1875 (Jan 10)*

- Unapproved and Misbranded Oral and Injectable Drugs Labeled for Prescription Use Containing Codeine Sulfate, Codeine Phosphate, or Dihydrocodeine Bitartrate; Enforcement Action Dates – *1879 (Jan 10)*
- Use of Innovative Packaging, Storage, and/or Disposal Systems to Address the Misuse and Abuse of Opioid Analgesics – *19619 (Apr 9)*

Environmental Impact Statements; Availability, etc.:
- Risk-Based Regulatory Framework and Strategy for Health Information Technology Report; Report and Web Site Location – *19100 (Apr 7)*

Funding Availability:
- Illinois Institute of Technology's National Center for Food Safety and Technology; Cooperative Agreement – *23360 (Apr 28)*

List of Recognized Standards:
- Recognition List Number 033; Modifications – *2453 (Jan 14)*
- Recognition List Number 034; Modifications – *4913 (Jan 30)*

Medical Devices:
- Authorization of Emergency Use of an In Vitro Diagnostic Device for Detection of Novel Influenza A (H7N9) Virus; Availability – *21768 (Apr 17)*
- Safety and Effectiveness Summaries for Premarket Approval Applications – *14053, 14053 (Mar 12)*

Meetings:
- Advancing Regulatory Science for High Throughput Sequencing Devices for Microbial Identification, etc. – *13062 (Mar 7)*
- Advancing the Development of Pediatric Therapeutics; Pediatric Bone Health – *7205 (Feb 6); 21473 (Apr 16)*
- Advisory Committees; Filing of Closed Meeting Reports – *10814 (Feb 26)*
- American Glaucoma Society/Supporting Innovation for Safe and Effective Minimally Invasive Glaucoma Surgery – *6203 (Feb 3)*
- Anesthesiology and Respiratory Therapy Devices Panel of the Medical Devices Advisory Committee – *1382 (Jan 8)*
- Anesthetic and Analgesic Drug Products Advisory Committee – *16010 (Mar 24)*
- Anti-Infective Drugs Advisory Committee – *8462 (Feb 12)*
- Application of Physiologically-Based Pharmacokinetic Modeling to Support Dose Selection – *8192 (Feb 11)*
- Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee – *1384 (Jan 8)*
- Biofilms, Medical Devices, and Anti-Biofilm Technology; Public Workshop – *4166 (Jan 24)*
- Blood Products Advisory Committee – *9909 (Feb 21)*
- Cardiovascular and Renal Drugs Advisory Committee – *1384 (Jan 8); 1646 (Jan 9); 13064 (Mar 7)*
- Characterizing and Communicating Uncertainty in the Assessment of Benefits and Risks in Drug Regulatory Decision-Making – *21475 (Apr 16)*
- Characterizing and Communicating Uncertainty in the Assessment of Benefits and Risks in Drug Regulatory Decision-Making; Public Workshop – *1877 (Jan 10)*
- Circulatory System Devices Panel, Medical Devices Advisory Committee – *20888 (Apr 14)*
- Clinical Trial Requirements, Regulations, Compliance, and Good Clinical Practice; Public Workshop – *3829 (Jan 23)*
- Endocrinologic and Metabolic Drugs Advisory Committee – *9911 (Feb 21)*
- FDA and Global Engagement: Progress on the Pathway to Global Product Safety – *18033 (Mar 31)*
- FDA/Xavier University PharmaLink Conference; Leadership in a Global Supply Chain – *9229 (Feb 18)*
- Fibromyalgia, Patient-Focused Drug Development; Rescheduling – *9468 (Feb 19)*
- Food and Drug Administration/Xavier University Global Medical Device Conference – *10815 (Feb 26)*
- Gastroenterology and Urology Devices Panel of the Medical Devices Advisory Committee – *8722 (Feb 13); 22147 (Apr 21)*
- Medical Countermeasures Initiative Regulatory Science Symposium – *9230 (Feb 18)*
- Medical Devices; The Case for Quality – *9469 (Feb 19)*
- Methods for Thrombogenicity Testing; Public Workshop – *14054 (Mar 12)*
- Microbiology Devices Panel of the Medical Devices Advisory Committee – *3388 (Jan 21)*
- Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee – *6908 (Feb 5)*
- Neurological Devices Panel of the Medical Devices Advisory Committee – *17155 (Mar 27)*
- Next-Generation Sequencing Technology, Data Formats Standardization and Promotion of Interoperability Protocols – *22147 (Apr 21)*
- Nonprescription Drugs Advisory Committee – *1381 (Jan 8); 20215 (Apr 11)*
- Nonprescription Drugs and Pulmonary-Allergy Drugs Advisory Committees – *1383 (Jan 8)*
- Oncologic Drugs Advisory Committee – *22146 (Apr 21)*
- Ophthalmic Devices Panel of the Medical Devices Advisory Committee – *11796 (Mar 3); 20889 (Apr 14)*
- Over-The-Counter Drug Monograph System; Past, Present, and Future – *10168 (Feb 24)*
- Patient-Focused Drug Development for Neurologic Manifestations of Inborn Errors of Metabolism – *22994 (Apr 25)*
- Pediatric Advisory Committee – *2452 (Jan 14); 18034 (Mar 31)*
- Pediatric Clinical Investigator Training Workshop – *23982 (Apr 29)*
- Postmarketing Requirements for the Class-Wide Extended-Release/Long-Acting Opioid Analgesics – *22499 (Apr 22)*
- Preparation for International Cooperation on Cosmetics Regulation – *22993 (Apr 25)*
- Proposal to Revoke Allergy Laboratories, Inc. License – *24443 (Apr 30)*
- Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee – *22995 (Apr 25)*
- Pulmonary Arterial Hypertension; Patient-Focused Drug Development – *7464 (Feb 7)*
- Risk Communications Advisory Committee – *398 (Jan 3); 3830 (Jan 23); 11797 (Mar 3)*
- Risk-Based Framework for Food and Drug Administration Safety and Innovation Act Health Information Technology; Public Workshop – *21473 (Apr 16)*
- Science Board – *3831 (Jan 23)*
- Science Board to the Food and Drug Administration – *1645 (Jan 9)*
- Serious Drug-Induced Liver Injury; Who Gets It? Who Doesn't? Why? – *7680 (Feb 10)*
- Society of Clinical Research Associates; Public Workshop – *9471 (Feb 19)*
- Standards for Interoperable Exchange of Information for Tracing of Human, Finished, Prescription Drugs, in Paper or Electronic Format; Workshop – *18562 (Apr 2)*
- Study Approaches and Methods to Evaluate Safety of Drugs and Biological Products During Pregnancy in Post-Approval Setting – *9469 (Feb 19)*
- Synergizing Efforts in Standards Development for Cellular Therapies and Regenerative Medicine Products; Public Workshop – *8462 (Feb 12)*
- Tobacco Products Scientific Advisory Committee – *9910 (Feb 21)*
- Vaccines and Related Biological Products Advisory Committee – *5439 (Jan 31); 8463 (Feb 12)*
- Voting and/or Nonvoting Consumer Representatives on Public Advisory Committees or Panels; Nominations – *16010 (Mar 24)*

National Environmental Policy Act:
- Canned Ackee, Frozen Ackee, and Other Ackee Products - Hypoglycin A Toxin – *21250 (Apr 15)*

New Drug Applications:
- AbbVie Inc., et al.; Acetaminophen; Withdrawals – *17156 (Mar 27)*
- Actavis Totowa, LLC, et al.; Acetaminophen; Withdrawals – *17163 (Mar 27)*
- Eli Lilly and Co., et al.; Withdrawals – *22501 (Apr 22)*
- Improving the Quality of Abbreviated Submissions – *3828 (Jan 23)*
- MK Laboratories, Inc., et al.; Propoxyphene Products – *13310 (Mar 10)*
- Phenylpropanolamine; Withdrawal of Approval – *9744 (Feb 20)*
- Xanodyne Pharmaceuticals, Inc., et al.; Propoxyphene Products – *13308 (Mar 10)*

Premarket Approvals:
- Watson Laboratories, Inc.; Bupropion Hydrochloride Extended-Release Tablets, 300 Milligrams; Withdrawal – *19626 (Apr 9)*

Priority Review Vouchers:
- Rare Pediatric Disease Product – *14055 (Mar 12)*

Regulatory Review Period for Patent Extensions:
- BRILINTA – *24444 (Apr 30)*
- DALIRESP – *3831 (Jan 23)*
- EYLEA – *18566 (Apr 2)*
- FIRAZYR – *18565 (Apr 2)*
- GADAVIST – *3832 (Jan 23)*
- MELAFIND SYSTEM – *19101 (Apr 7)*
- NOVOTFF-100A SYSTEM – *18567 (Apr 2)*
- NULOJIX – *18036 (Mar 31)*
- ONSIOR – *18563 (Apr 2)*
- POTIGA – *18564 (Apr 2)*
- PREVNAR-13 – *18035 (Mar 31)*

Requests for Nominations:
- Nonvoting Industry Representatives on Public Advisory Panels – *3390 (Jan 21)*
- Nonvoting Industry Representatives on the Device Good Manufacturing Practice Advisory Committee – *3389 (Jan 21)*
- Pharmacy Compounding Advisory Committee – *2178 (Jan 13)*
- Pharmacy Compounding Advisory Committee, Nonvoting Industry Representatives – *2177 (Jan 13)*
- Pharmacy Compounding Advisory Committee, Voting Members – *2179 (Jan 13)*
- Science Board – *6204 (Feb 3)*

Selections Process for Non-Voting Industry Representatives – *22148 (Apr 21)*